标题
Drug repurposing approach to fight COVID-19
作者
关键词
-
出版物
Pharmacological Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-05
DOI
10.1007/s43440-020-00155-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Compounds with therapeutic potential against novel respiratory 2019 coronavirus
- (2020) Miguel Angel Martinez ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- (2020) Calvin J Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
- (2020) Xin Liu et al. Journal of Genetics and Genomics
- The 2019‐new coronavirus epidemic: Evidence for virus evolution
- (2020) Domenico Benvenuto et al. JOURNAL OF MEDICAL VIROLOGY
- The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019
- (2020) Wenzheng Han et al. JOURNAL OF MEDICAL VIROLOGY
- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Coronavirus puts drug repurposing on the fast track
- (2020) Charlotte Harrison NATURE BIOTECHNOLOGY
- First Case of 2019 Novel Coronavirus in the United States
- (2020) Michelle L. Holshue et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug repositioning for rare diseases: Knowledge-based success stories
- (2020) Daniel Scherman et al. THERAPIE
- Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue
- (2020) Kun-Ling Shen et al. World Journal of Pediatrics
- Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
- (2020) Syed Faraz Ahmed et al. Viruses-Basel
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
- (2020) Camillo Sargiacomo et al. Aging-US
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
- (2020) J.-M. Michot et al. ANNALS OF ONCOLOGY
- COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD
- (2020) Carina Mihai et al. ANNALS OF THE RHEUMATIC DISEASES
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
- (2020) Babak Sayad et al. ARCHIVES OF MEDICAL RESEARCH
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
- (2020) Paola Toniati et al. AUTOIMMUNITY REVIEWS
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
- (2020) Hua-Hao Fan et al. CHINESE MEDICAL JOURNAL
- Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
- (2020) Zhongliang Wang et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
- (2020) Melissa Bersanelli Immunotherapy
- Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
- (2020) Naveen Vankadari INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
- (2020) Christian A. Devaux et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Teicoplanin: an alternative drug for the treatment of COVID-19?
- (2020) Sophie Alexandra Baron et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
- (2020) Sukbin Jang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Lack of Antiviral Activity of Darunavir against SARS-CoV-2
- (2020) Sandra De Meyer et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- COVID-19 and RAS: Unravelling an Unclear Relationship
- (2020) Damiano D’Ardes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase
- (2020) Rameez Jabeer Khan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
- (2020) Abdo A. Elfiky JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach
- (2020) Salman Ali Khan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
- (2020) Junmei Wang Journal of Chemical Information and Modeling
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
- (2020) Lisi Deng et al. JOURNAL OF INFECTION
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds
- (2020) Anh-Tien Ton et al. Molecular Informatics
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
- (2020) Muthiah Vaduganathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA
- (2020) José Antonio Encinar et al. Viruses-Basel
- Drug treatment options for the 2019-new coronavirus (2019-nCoV)
- (2020) Hongzhou Lu BioScience Trends
- Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment
- (2020) Zhenwei Wang et al. BioScience Trends
- Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
- (2020) David S. Fedson et al. mBio
- Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury
- (2020) Fengming Huang et al. PLoS Pathogens
- The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
- (2020) Xi Wang et al. Cell Discovery
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
- (2020) Yadi Zhou et al. Cell Discovery
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk
- (2020) Puja Mehta et al. EUROPEAN RESPIRATORY JOURNAL
- Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease
- (2020) Son Tung Ngo et al. Journal of Chemical Information and Modeling
- Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- SARS‐CoV‐2 and SARS‐CoV: Virtual screening of potential inhibitors targeting RNA‐dependent RNA polymerase activity (NSP12)
- (2020) Zijing Ruan et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study
- (2020) Haiyan Qiu et al. LANCET INFECTIOUS DISEASES
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
- (2020) F. La Rosée et al. LEUKEMIA
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
- (2020) Bhumi Shah et al. LIFE SCIENCES
- Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
- (2020) Emanuelle Machado Marinho et al. MICROBIAL PATHOGENESIS
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management
- (2020) Mina T. Kelleni PHARMACOLOGICAL RESEARCH
- Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial
- (2020) José Meneses Calderón et al. Trials
- The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
- (2020) Hussin A. Rothan et al. VIROLOGY
- Dexamethasone in the management of covid -19
- (2020) Raymond M Johnson et al. BMJ-British Medical Journal
- Pharmacotherapics Advice in Guidelines for COVID-19
- (2020) Zhang-Ren Chen et al. Frontiers in Pharmacology
- Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa
- (2020) Helen Brotherton et al. Lancet Global Health
- Ribavirin and Interferon Therapy for Critically Ill Patients with the Middle East Respiratory Syndrome: A multicenter observational study
- (2019) Yaseen Arabi et al. CLINICAL INFECTIOUS DISEASES
- Role of Endoplasmic Reticulum-Associated Proteins in Flavivirus Replication and Assembly Complexes
- (2019) Hussin A. Rothan et al. Pathogens
- Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care
- (2019) Virginia A Triant et al. JOURNAL OF INFECTIOUS DISEASES
- Clinical regimens of favipiravir inhibit Zika virus (ZIKV) replication in the Hollow Fiber Infection Model (HFIM)
- (2018) Camilly P. Pires de Mello et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of the RNA Pseudoknot within the 3′ End of the Porcine Reproductive and Respiratory Syndrome Virus Genome as a Pathogen-Associated Molecular Pattern To Activate Antiviral Signaling via RIG-I and Toll-Like Receptor 3
- (2018) Sha Xie et al. JOURNAL OF VIROLOGY
- Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
- (2018) Yaseen M. Arabi et al. Trials
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- Hydroxychloroquine retinopathy
- (2017) I H Yusuf et al. EYE
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents
- (2017) Emilio Molina-Cuadrado et al. European Journal of Hospital Pharmacy-Science and Practice
- Tocilizumab (Actemra)
- (2017) Martin Sheppard et al. Human Vaccines & Immunotherapeutics
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
- Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)
- (2016) G.B. John Mancini et al. CANADIAN JOURNAL OF CARDIOLOGY
- Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
- (2016) Hisham Abdallah et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- In silico methods for drug repurposing and pharmacology
- (2016) Rachel A. Hodos et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- Retinal toxicity with Ritonavir
- (2016) International Journal of Ophthalmology
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
- (2016) Jean-François Rossignol Journal of Infection and Public Health
- Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
- (2016) Jonathan Shuter Therapeutics and Clinical Risk Management
- Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever
- (2015) Brian B. Gowen et al. ANTIVIRAL RESEARCH
- Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications
- (2015) Kulbhushan Tikoo et al. BIOCHEMICAL PHARMACOLOGY
- A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects
- (2015) Li Zheng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- (2015) Jasper Fuk-Woo Chan et al. JOURNAL OF INFECTIOUS DISEASES
- Total chemical synthesis of human interferon alpha-2b via native chemical ligation
- (2015) Jing Li et al. JOURNAL OF PEPTIDE SCIENCE
- Protein localization vector propagation: a method for improving the accuracy of drug repositioning
- (2015) Yunku Yeu et al. Molecular BioSystems
- Pericentral Retinopathy and Racial Differences in Hydroxychloroquine Toxicity
- (2015) Ronald B. Melles et al. OPHTHALMOLOGY
- Reply to “Statins may decrease the Fatality Rate of MERS Infection”
- (2015) Allison L. Totura et al. mBio
- Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection: FIG 1
- (2015) Shu Yuan mBio
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
- (2014) Julie Dyall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
- (2014) Lisa Oestereich et al. ANTIVIRAL RESEARCH
- Arbidol as a broad-spectrum antiviral: An update
- (2014) Julie Blaising et al. ANTIVIRAL RESEARCH
- Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1
- (2014) Kam-Leung Siu et al. Cell and Bioscience
- Coronavirus infection, ER stress, apoptosis and innate immunity
- (2014) To S. Fung et al. Frontiers in Microbiology
- Drug Interactions and Antiretroviral Drug Monitoring
- (2014) Matthew Foy et al. Current HIV/AIDS Reports
- Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans
- (2013) Pan Deng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cheminformatics at the interface of medicinal chemistry and proteomics
- (2013) Uwe Koch et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
- (2013) Nianshuang Wang et al. CELL RESEARCH
- Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
- (2013) Benoit Chauvin et al. CLINICAL PHARMACOKINETICS
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
- (2013) Darryl Falzarano et al. NATURE MEDICINE
- Imbalance Between Pulmonary Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in Acute Respiratory Distress Syndrome
- (2013) Roelie M. Wösten-van Asperen et al. Pediatric Critical Care Medicine
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
- (2013) Darryl Falzarano et al. Scientific Reports
- Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis
- (2013) Naba R Mainali et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Antihypertensive Drugs in Patients Treated with Antiretroviral
- (2012) Hélène Peyriere et al. ANNALS OF PHARMACOTHERAPY
- Network medicine: linking disorders
- (2012) Rosario M. Piro HUMAN GENETICS
- Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions
- (2012) David Burger et al. JOURNAL OF HEPATOLOGY
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
- (2012) Sandrine Belouzard et al. Viruses-Basel
- Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methods
- (2011) B.E. Steinberg et al. ANTIVIRAL RESEARCH
- Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
- (2011) Dale L Barnard et al. Future Virology
- Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist
- (2011) Roelie M Wösten-van Asperen et al. JOURNAL OF PATHOLOGY
- Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever
- (2011) Michelle Mendenhall et al. PLoS Neglected Tropical Diseases
- ACE2: more of Ang-(1–7) or less Ang II?
- (2010) Carlos M Ferrario CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Características químicas, mecanismo de acción y actividad antiviral de darunavir
- (2010) Juan Pasquau Liaño et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Genomic Characterization of Severe Acute Respiratory Syndrome-Related Coronavirus in European Bats and Classification of Coronaviruses Based on Partial RNA-Dependent RNA Polymerase Gene Sequences
- (2010) J. F. Drexler et al. JOURNAL OF VIROLOGY
- Coronavirus Genomics and Bioinformatics Analysis
- (2010) Patrick C. Y. Woo et al. Viruses-Basel
- Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax
- (2009) H.-S. Lim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimizing ribavirin dosage: A new challenge to improve treatment efficacy in genotype 1 hepatitis C patients
- (2009) V. Loustaud-Ratti et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
- The spike protein of SARS-CoV — a target for vaccine and therapeutic development
- (2009) Lanying Du et al. NATURE REVIEWS MICROBIOLOGY
- The 8ab protein of SARS-CoV is a luminal ER membrane-associated protein and induces the activation of ATF6
- (2009) Shu-Chiun Sung et al. VIROLOGY
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
- (2008) N Nishimoto et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors
- (2008) B. L. Robbins et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C
- (2008) J. Morello et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started